SCHEMBL90619

SCHEMBL90619

COCCCN1C(=O)C(C)(C)Oc2ccc(N(C(=O)[C@@H]3C[C@H](C(=O)NC(C)c4ccc(OC)cc4)CN(C(=O)OC(C)(C)C)C3)C3CC3)cc21

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
REN P00797 3/20 0.45
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
EPHX2 P34913 1/20 0.34
CNR1 P21554 1/20 0.34
KMT2A Q03164 3/20 0.33
POLB P06746 1/20 0.33
ALDH1A1 P00352 2/20 0.33
ACACB O00763 2/20 0.33
LMNA P02545 1/20 0.33
MEN1 O00255 2/20 0.32
CASP1 P29466 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
USP2 O75604 1/20 0.32
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32
STS P08842 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89689 1.00 REN (0.45) RENHPGDNPSR1EPHX2CNR1
SCHEMBL89163 0.94 REN (0.46) RENNPSR1KMT2APOLBALDH1A1
SCHEMBL89658 0.94 REN (0.46) RENNPSR1KMT2APOLBALDH1A1
SCHEMBL90013 0.92 REN (0.48) RENHPGDEPHX2KMT2APOLB
SCHEMBL90110 0.92 REN (0.48) RENHPGDEPHX2KMT2APOLB
SCHEMBL90060 0.92 REN (0.48) RENKMT2APOLBALDH1A1MEN1
SCHEMBL89813 0.90 REN (0.50) RENHPGDEPHX2KMT2APOLB
SCHEMBL90280 0.90 REN (0.50) RENHPGDEPHX2KMT2APOLB
SCHEMBL90290 0.90 REN (0.49) RENHPGDEPHX2KMT2APOLB
SCHEMBL89425 0.90 REN (0.49) RENHPGDEPHX2KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 REN 1/4885HPGD 723/4885NPSR1 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.